What is New Objective?
New Objective operates at the intersection of advanced engineering and biological discovery, specializing in the development of proprietary PicoTip technologies. With a legacy spanning over 25 years, the company has become synonymous with high-performance nanospray emitters, columns, and integrated sources that facilitate complex proteomics research. Their product ecosystem, anchored by the PicoChip and FlowChip platforms, is engineered to address the rigorous demands of both nanoflow and microflow applications. By consistently delivering hardware that enhances sensitivity and throughput, New Objective has become an essential partner for laboratories seeking to push the boundaries of molecular analysis, as evidenced by their contribution to over 10,000 peer-reviewed scientific publications.
How much funding has New Objective raised?
New Objective has raised a total of $375K across 2 funding rounds:
Debt
$150K
Debt
$225K
Debt (2020): $150K with participation from PPP
Debt (2021): $225K led by PPP
Key Investors in New Objective
PPP
Public-Private Partnership
What's next for New Objective?
Looking ahead, the strategic deployment of the $225K capital is expected to accelerate the company's R&D initiatives, particularly in the refinement of next-generation microfluidic interfaces. As the proteomics market shifts toward higher throughput and automated workflows, New Objective is well-positioned to capitalize on the increasing demand for standardized, high-reproducibility instrumentation. The firm's focus will likely remain on expanding its international distribution networks and deepening its integration with major mass spectrometry manufacturers. By maintaining its commitment to technical excellence and scientific collaboration, New Objective is poised to remain a dominant force in the life sciences supply chain, effectively bridging the gap between raw analytical data and actionable biological insights.
See full New Objective company page
